Jefferies Upgrades Quest Diagnostics to Buy, Raises Price Target to $155
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Brian Tanquilut upgraded Quest Diagnostics (NYSE:DGX) from Hold to Buy and increased the price target from $140 to $155, indicating a positive outlook on the company's future performance.
February 07, 2024 | 11:23 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Quest Diagnostics upgraded by Jefferies from Hold to Buy with a raised price target from $140 to $155.
The upgrade from Hold to Buy by a reputable analyst at Jefferies, along with a significant increase in the price target, suggests a strong confidence in Quest Diagnostics' future performance. This is likely to positively influence investor sentiment and potentially lead to an increase in the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100